07:26 AM EST, 11/27/2024 (MT Newswires) -- PTC Therapeutics ( PTCT ) said Wednesday it agreed to sell its Rare Pediatric Disease Priority Review Voucher for $150 million, upon completion of the transaction.

The voucher was granted on Nov. 13 along with the US Food and Drug Administration's approval of Kebilidi to treat children and adults with AADC deficiency.

Priority review vouchers are awarded by the FDA to incentivize the drug development for rare pediatric diseases.